drugset / Trial / NCT00004647

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

NCT00004647

RandomizedDouble-blindTreatment

Summary

OBJECTIVES: I. Assess the efficacy and toxicity of mexiletine in the management of paresthesias and pain in patients with diabetic neuropathy.

Timeline

Start
1993-03
Primary completion
Completion
1999-02

Publications

  • Background Bertorini TE, Alzagatiti BI, Horner LH, et al.: Electrophysiological effects of mexiletine in painful neuropathy. Nerve 21(11): 1576, 1998.

Drugs

EvaluationDrugModalityDoseRoute
Subject Mexiletine Small molecule Oral

Indications